M. Bolis

A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader molecules

This study identifies a SWI/SNF-targeting therapy effective against a double-negative prostate cancer subtype, showing it reduces viability in both AR-dependent and WNT-dependent models.

JUN mediates senescence and immune cell recruitment to prevent prostate cancer progression

This study shows JUN suppresses prostate cancer progression by inducing senescence and immune cell recruitment, with JUN depletion accelerating tumor growth.

Cancer-specific association between Tau (MAPT) and cellular pathways, clinical outcome, and drug response

The paper analyzes MAPT expression across cancer types to show its association with cancer hallmarks, clinical outcomes, and drug response, highlighting context-specific roles.

Tau protein modulates an epigenetic mechanism of cellular senescence

The paper investigates how Tau protein affects epigenetic regulation of cellular senescence by analyzing transcriptome data from Tau-depleted cells.

Minor intron splicing efficiency increases with the development of lethal prostate cancer

The paper shows that minor intron splicing efficiency increases in castration-resistant prostate cancer and that inhibiting the minor spliceosome reduces tumor burden.

Patient-derived xenografts and organoids model therapy response in prostate cancer

This study develops a patient-derived xenograft (PDX) model of prostate cancer that mimics disease stages and identifies drug sensitivities in metastatic cases.

Dual Functions of SPOP and ERG Dictate Androgen Therapy Responses in Prostate Cancer

This study shows that SPOP and ERG mutations in prostate cancer have opposing effects on androgen receptor signaling and therapy response.